2020 - CARISMA Therapeutics

News & Events

November 24, 2020

CARISMA THERAPEUTICS TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN DECEMBER

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, the President & CEO, will present at two virtual investor conferences in December 2020. Piper Sandler 32nd Annual Virtual Healthcare Conference November 30, 2020- December 3, 2020 Presentations will be available for registered attendees via the Piper Sandler […]

November 9, 2020

CARISMA to Present New Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

PHILADELPHIA, Nov. 9, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new preclinical findings accepted for presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (November 9 – 14, 2020). Click here for more information.

October 8, 2020

CARISMA Therapeutics to Present at Upcoming Healthcare Industry Conferences

PHILADELPHIA, Oct. 8, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at upcoming virtual healthcare industry conferences in October 2020.

October 5, 2020

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Oct. 5, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual investor conferences in October 2020. Click here for more information.

August 25, 2020

CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

PHILADELPHIA, Aug. 25, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications. […]

August 3, 2020

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, July 30, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual conferences in August 2020. Click here for more information.

July 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company’s lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). […]

May 21, 2020

Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences

PHILADELPHIA, May 21, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming virtual healthcare investor conferences in May and June 2020.Click here for more information.

May 15, 2020

New Data Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

Carisma Therapeutics expands on foundational first-of-its-kind engineered macrophage cell therapy platform study and explores time-reducing isolation-to-infusion pathway. For full press release, click here

March 23, 2020

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors. For full press release, click here.